{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/205891","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02415595","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"true","masked_investigator":"true","masked_subject":"true","masking_description":"","no_masking":"false"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Arm 1: BMS-955176 60 mg + TDF/FTC","arm_group_description":"BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally","arm_type":"Experimental"},{"arm_group_label":"Arm 2: BMS-955176 120 mg + TDF/FTC","arm_group_description":"BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally","arm_type":"Experimental"},{"arm_group_label":"Arm 3: BMS-955176 180 mg + TDF/FTC","arm_group_description":"BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally","arm_type":"Experimental"},{"arm_group_label":"Arm 4: EFV + TDF/FTC","arm_group_description":"BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day","arm_type":"Active Comparator"}],"assignment":"Parallel Assignment","brief_summary":"The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Dose-finding study of BMS-955176 to treat HIV-1 Infected treatment-naive adults","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:33:16","criteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n  - Men and non-pregnant women, at least 18 years of age\n  - Antiretroviral treatment-naïve; defined as no current or previous exposure to > 1 week of an antiretroviral drug\n  - Plasma HIV-1 RNA ≥ 1000 copies/mL\n  - CD4 T-cell count > 200 cells/mm3\n\nExclusion Criteria:\n  - Resistance or partial resistance to any study drug determined by tests at Screening\n  - Current or historical genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors  \n  - Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)  \n  - Blood tests that indicate normal liver function\n  - Hemoglobin < 8.0 g/dL, platelets < 50,000 cells/mm3","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Terminated (halted prematurely)","display_status_internal":"RECSTATUS_I_TERMINATED_HALT_P","endpoint":"","enrollment":"210","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"1cb8b624-f520-5aa5-9471-c8ad516bb11e","internal":{"content":null,"contentDigest":"0d91346fa4b15158b7dccc49f79852a8","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n  - Men and non-pregnant women, at least 18 years of age\n  - Antiretroviral treatment-naïve; defined as no current or previous exposure to > 1 week of an antiretroviral drug\n  - Plasma HIV-1 RNA ≥ 1000 copies/mL\n  - CD4 T-cell count > 200 cells/mm3\n\nExclusion Criteria:\n  - Resistance or partial resistance to any study drug determined by tests at Screening\n  - Current or historical genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors  \n  - Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)  \n  - Blood tests that indicate normal liver function\n  - Hemoglobin < 8.0 g/dL, platelets < 50,000 cells/mm3","interventions":[{"arm_group_label":"Arm 3: BMS-955176 180 mg + TDF/FTC","intervention_description":"HIV Maturation Inhibitor","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Arm 1: BMS-955176 60 mg + TDF/FTC","intervention_description":"HIV Maturation Inhibitor","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Arm 2: BMS-955176 120 mg + TDF/FTC","intervention_description":"HIV Maturation Inhibitor","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Arm 4: EFV + TDF/FTC","intervention_description":"EFV","intervention_name":"EFV","intervention_type":"Drug"},{"arm_group_label":"Arm 3: BMS-955176 180 mg + TDF/FTC","intervention_description":"TDF/FTC","intervention_name":"TDF/FTC","intervention_type":"Drug"},{"arm_group_label":"Arm 1: BMS-955176 60 mg + TDF/FTC","intervention_description":"TDF/FTC","intervention_name":"TDF/FTC","intervention_type":"Drug"},{"arm_group_label":"Arm 4: EFV + TDF/FTC","intervention_description":"TDF/FTC","intervention_name":"TDF/FTC","intervention_type":"Drug"},{"arm_group_label":"Arm 2: BMS-955176 120 mg + TDF/FTC","intervention_description":"TDF/FTC","intervention_name":"TDF/FTC","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"08/21/2017 00:00:00","links":[{"description":"BMS clinical trial educational resource","url":"http://www.bms.com/studyconnect/Pages/home.aspx"},{"description":"BMS Clinical Trial Information","url":"http://ctr.bms.com/ctd/start.do"},{"description":"FDA Safety Alerts and Recalls","url":"http://www.fda.gov/MEDWATCH/safety.htm"},{"description":"Investigator Inquiry form","url":"http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"}],"locations":[{"City":"Milano","Latitude":"45.5000627","CountryDisplay":"Italy","Longitude":"9.2273552","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rosario","Latitude":"-32.9622313","CountryDisplay":"Argentina","Longitude":"-60.6255364","Name":"GSK Investigational Site","StateDisplay":"Santa Fe","PostalCode":"2000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Santiago de Compostela","Latitude":"42.8663831","CountryDisplay":"Spain","Longitude":"-8.5638609","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"15706","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5411171","CountryDisplay":"Germany","Longitude":"13.3509304","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"13353","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.4658033","CountryDisplay":"Germany","Longitude":"13.3448464","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"12157","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Wroclaw","Latitude":"51.1249084","CountryDisplay":"Poland","Longitude":"17.0259655","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"50-220","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lyon cedex 04","Latitude":"45.764043","CountryDisplay":"France","Longitude":"4.835659","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"69317","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Quebec","Latitude":"46.7691394","CountryDisplay":"Canada","Longitude":"-71.2832751","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"G1V 4G2","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Santiago","Latitude":"-33.4488897","CountryDisplay":"Chile","Longitude":"-70.6692655","Name":"GSK Investigational Site","StateDisplay":"Región Metro De Santiago","PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Edinburgh","Latitude":"55.9621052","CountryDisplay":"United Kingdom","Longitude":"-3.2338808","Name":"GSK Investigational Site","StateDisplay":"Midlothian","PostalCode":"EH4 2XU","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Santiago","Latitude":"-33.4488897","CountryDisplay":"Chile","Longitude":"-70.6692655","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"8360159","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Córdoba","Latitude":"-31.4200833","CountryDisplay":"Argentina","Longitude":"-64.1887761","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"X5000JJS","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Nantes","Latitude":"47.196147","CountryDisplay":"France","Longitude":"-1.537269","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"44093","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Durango","Latitude":"24.0278164","CountryDisplay":"Mexico","Longitude":"-104.6616973","Name":"GSK Investigational Site","StateDisplay":"Durango","PostalCode":"34000","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Ottawa","Latitude":"45.4007277","CountryDisplay":"Canada","Longitude":"-75.6492669","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"K1H 8L6","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Monza","Latitude":"45.5845001","CountryDisplay":"Italy","Longitude":"9.2744485","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20900","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Alcala de Henares","Latitude":"40.5108369","CountryDisplay":"Spain","Longitude":"-3.3237824","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28805","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Szczecin","Latitude":"53.4512519","CountryDisplay":"Poland","Longitude":"14.5125474","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"71-252","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ciudad Autonoma de Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1181ACH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"León","Latitude":"21.1211701","CountryDisplay":"Mexico","Longitude":"-101.6826359","Name":"GSK Investigational Site","StateDisplay":"Guanajuato","PostalCode":"37000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"DF","Latitude":"19.2871869","CountryDisplay":"Mexico","Longitude":"-99.1705253","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"14000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Warszawa","Latitude":"52.2347373","CountryDisplay":"Poland","Longitude":"20.9754476","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"01-201","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"1202","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5411171","CountryDisplay":"Germany","Longitude":"13.3509304","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"13353","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Muenchen","Latitude":"48.1443383","CountryDisplay":"Germany","Longitude":"11.5548236","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80335","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Beverly Hills","Latitude":"34.0661071","CountryDisplay":"United States","Longitude":"-118.3841777","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90211","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7440941","CountryDisplay":"United States","Longitude":"-84.377861","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30312","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Worth","Latitude":"32.7248887","CountryDisplay":"United States","Longitude":"-97.3138554","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"76104","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mexico City","Latitude":"19.2892862","CountryDisplay":"Mexico","Longitude":"-99.1580693","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"CP 14080","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Essen","Latitude":"51.4556432","CountryDisplay":"Germany","Longitude":"7.0115552","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"45122","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Madrid","Latitude":"40.4998271","CountryDisplay":"Spain","Longitude":"-3.6876803","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28034","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Hannover","Latitude":"52.3763832","CountryDisplay":"Germany","Longitude":"9.8026933","Name":"GSK Investigational Site","StateDisplay":"Niedersachsen","PostalCode":"30625","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bydgoszcz","Latitude":"53.1221885","CountryDisplay":"Poland","Longitude":"18.0114555","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"85-030","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"London","Latitude":"51.5190259","CountryDisplay":"United Kingdom","Longitude":"-0.058075","Name":"GSK Investigational Site","StateDisplay":"London","PostalCode":"E1 1BB","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.4844854","CountryDisplay":"United Kingdom","Longitude":"-0.1817772","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SW10 9NH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Santa Fe","Latitude":"35.616067","CountryDisplay":"United States","Longitude":"-105.8525154","Name":"GSK Investigational Site","StateDisplay":"New Mexico","PostalCode":"87505","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Nice","Latitude":"43.7101728","CountryDisplay":"France","Longitude":"7.2619532","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"06202","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bloemfontein","Latitude":"-29.13184","CountryDisplay":"South Africa","Longitude":"26.1950214","Name":"GSK Investigational Site","StateDisplay":"Free State","PostalCode":"9301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Le Kremlin-Bicêtre","Latitude":"48.810108","CountryDisplay":"France","Longitude":"2.356972","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"94276","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Paris","Latitude":"48.830759","CountryDisplay":"France","Longitude":"2.359204","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75013","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.5179048","CountryDisplay":"Canada","Longitude":"-73.558878","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 4P9","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0664817","CountryDisplay":"United States","Longitude":"-118.3520389","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90036","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.5170141","CountryDisplay":"United Kingdom","Longitude":"-0.1742622","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"W2 1NY","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Edmonton","Latitude":"53.5281769","CountryDisplay":"Canada","Longitude":"-113.528673","Name":"GSK Investigational Site","StateDisplay":"Alberta","PostalCode":"T6G 2G3","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Montreal","Latitude":"45.50071","CountryDisplay":"Canada","Longitude":"-73.574572","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H3A 1T1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Badalona","Latitude":"41.474766","CountryDisplay":"Spain","Longitude":"2.2285864","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08916","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Dortmund","Latitude":"51.5081979","CountryDisplay":"Germany","Longitude":"7.4416173","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"44137","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bonn","Latitude":"50.6980735","CountryDisplay":"Germany","Longitude":"7.0871788","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"53127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.4745831","CountryDisplay":"Canada","Longitude":"-73.5980739","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H4A 3J1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tulsa","Latitude":"36.1005816","CountryDisplay":"United States","Longitude":"-95.9251211","Name":"GSK Investigational Site","StateDisplay":"Oklahoma","PostalCode":"74135","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milano","Latitude":"45.5145841","CountryDisplay":"Italy","Longitude":"9.1358629","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20157","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Deland","Latitude":"29.0128283","CountryDisplay":"United States","Longitude":"-81.3729372","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32720","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.5152072","CountryDisplay":"Canada","Longitude":"-73.5562284","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 5B1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fracc. Las Americas","Latitude":"21.9005906","CountryDisplay":"Mexico","Longitude":"-102.3020115","Name":"GSK Investigational Site","StateDisplay":"Aguascalientes","PostalCode":"20020","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bergamo","Latitude":"45.681736","CountryDisplay":"Italy","Longitude":"9.6490085","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"24127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Duesseldorf","Latitude":"51.1974375","CountryDisplay":"Germany","Longitude":"6.7898817","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"40225","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Paris","Latitude":"48.8293647","CountryDisplay":"France","Longitude":"2.4265406","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75012","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tooting, London","Latitude":"51.426561","CountryDisplay":"United Kingdom","Longitude":"-0.1760824","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SW17 0QT","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Buenos Aires","Latitude":"-34.6213576","CountryDisplay":"Argentina","Longitude":"-58.3773266","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"1141","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4473608","CountryDisplay":"Spain","Longitude":"-3.7384311","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28040","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Santiago","Latitude":"-33.4488897","CountryDisplay":"Chile","Longitude":"-70.6692655","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"7560994","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Winnipeg","Latitude":"49.9042982","CountryDisplay":"Canada","Longitude":"-97.1585239","Name":"GSK Investigational Site","StateDisplay":"Manitoba","PostalCode":"R3A 1R9","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Paris Cedex 10","Latitude":"48.856614","CountryDisplay":"France","Longitude":"2.3522219","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75475","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1340355","CountryDisplay":"Germany","Longitude":"11.5571732","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80336","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Decatur","Latitude":"33.8092255","CountryDisplay":"United States","Longitude":"-84.2805478","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"03/14/2019 12:41:02","number_of_arms":"4","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults","org_study_id":"205891","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Terminated (Halted Prematurely) - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 2","primary_compl_date":"05/26/2016 00:00:00","primary_outcomes":[{"outcome_description":"Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV 1 RNA <40 c/mL at Week 24 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window (18 to 30 weeks) to determine response. Analysis was performed on mITT Population, which comprised of randomized participants who received at least 1 dose of BMS-955176/GSK3532795 or EFV.","outcome_measure":"Number of participants with plasma HIV-1 ribonucleic acid (RNA) <40 copies per milliliter (c/mL) at Week 24 using Food and Drug Administration (FDA) snapshot algorithm","outcome_time_frame":"Week 24","outcome_safety_issue":null}],"product_name":"BMS-955176;GSK2326285;efavirenz;emtricitabine;tenofovir disoproxil fumarate","product_name_OneLinkTx":"","secondary_ids":[{"id":"2013-005487-26","id_type":"EudraCT Number","id_domain":""},{"id":"AI468-038","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV 1 RNA <40 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. The analysis was performed using mITT Population (observed), which consisted of participants in the mITT Population excluding participants who had no HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). The data was not collected for Week 96 analysis; as the study was terminated early. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).","outcome_measure":"Number of participants with plasma HIV-1 RNA < 40 c/mL at Weeks 48 and 96 using FDA snapshot algorithm","outcome_time_frame":"Weeks 48 and 96","outcome_safety_issue":null},{"outcome_description":"Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV-1 RNA <200 c/mL at Week 24 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response.","outcome_measure":"Number of participants with plasma HIV-1 RNA < 200 c/mL at Week 24 using FDA snapshot algorithm","outcome_time_frame":"Week 24","outcome_safety_issue":null},{"outcome_description":"Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV-1 RNA <200 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. The analysis was performed using mITT Population (observed), which consisted of participants in the mITT Population excluding participants who had no HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). The data was not collected for Week 96 analysis; as the study was terminated early. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).","outcome_measure":"Number of participants with plasma HIV-1 RNA < 200 c/mL at Weeks 48 and 96","outcome_time_frame":"Weeks 48 and 96","outcome_safety_issue":null},{"outcome_description":"The emergence of genotypic resistance among samples selected for drug resistance testing were assessed by searching for all reverse transcriptase substitutions and protease inhibitor substitutions listed in the International Acquired Immunodeficiency Syndrome (AIDS) Society-United States of America (IAS-USA) list of HIV-1 drug resistance mutations. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early. The emergence of genotypic resistance is presented for participants in the mITT Population who had Baseline and on-treatment genotypic resistance testing and who had successful sequencing.","outcome_measure":"Number of participants with newly emergent genotypic resistance using all on-treatment isolates","outcome_time_frame":"Week 24","outcome_safety_issue":null},{"outcome_description":"Phenotypic resistance to a drug is defined as a fold change (i.e., ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of the reference strain) which is greater than the cut-off for reduced susceptibility. Emergent phenotypic resistance to BMS-955176/GSK3532795 was defined as a Baseline fold change IC50<= 3 and an on-treatment fold change IC50>3. The number of participants with newly emergent phenotypic resistance is presented for participants in the mITT Population who had Baseline and on-treatment phenotypic resistance testing. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early.","outcome_measure":"Number of participants with newly emergent phenotypic resistance using all on-treatment isolates","outcome_time_frame":"Week 24","outcome_safety_issue":null},{"outcome_description":"Blood samples were collected for analysis of HIV-1 RNA. Values obtained at Day 1 were considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Change from Baseline in plasma HIV-1 RNA (log10) is summarized over time for the mITT Population using observed values, which excluded participants without HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.","outcome_measure":"Change from Baseline in logarithm to the base 10 (log10) HIV-1 RNA over time","outcome_time_frame":"Baseline (Day 1) and Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84","outcome_safety_issue":null},{"outcome_description":"CD4+ T-cell counts was assessed using flow cytometry. Values obtained at Day 1 were considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Change from Baseline in CD4+T- cell counts is summarized over time for the mITT Population using observed values, which excluded participants without HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.","outcome_measure":"Change from Baseline in cluster of differentiation (CD)4+ thymus (T)-cell counts over time","outcome_time_frame":"Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84","outcome_safety_issue":null},{"outcome_description":"CD4+ T-cell counts overall was assessed using flow cytometry. Values obtained at Day 1 were considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Change from Baseline in percentage of CD4+T- cell counts is summarized over time for the mITT Population using observed values, which excluded participants without HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.","outcome_measure":"Change from Baseline in the percentage of CD4+ T-cells over time","outcome_time_frame":"Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84","outcome_safety_issue":null},{"outcome_description":"Any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE. Number of participants with SAEs and AELDs is summarized.","outcome_measure":"Number of participants with serious adverse events (SAEs) and adverse events leading to discontinuation (AELD)","outcome_time_frame":"Up to Week 96","outcome_safety_issue":null},{"outcome_description":"The occurrence of new AIDS defining events that is CDC class C events is presented.","outcome_measure":"Number of participants with at least one Centers for Disease Control (CDC) class C events","outcome_time_frame":"Up to Week 96","outcome_safety_issue":null},{"outcome_description":"Serial blood samples were collected at indicated time points for intensive pharmacokinetic (PK) assessment. The PK assessments were performed on evaluable PK Population, a sub-population which included all treated participants who had adequate PK profiles.","outcome_measure":"Maximum observed plasma concentration (Cmax), observed pre-dose plasma concentration (C0) and observed plasma concentration at the end of a dosing interval (Ctau) of BMS-955176/GSK3532795","outcome_time_frame":"Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 (evening pre-dose) and 24 hours (morning pre-dose) at Week 2 (Days 12 to 16)","outcome_safety_issue":null},{"outcome_description":"Serial blood samples were collected at indicated time points for intensive PK assessment.","outcome_measure":"Time of maximum observed plasma concentration (Tmax) of BMS-955176/GSK3532795","outcome_time_frame":"Pre-dose (morning) and 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 (evening pre-dose) and 24 hours (morning pre-dose) at Week 2 (Days 12 to 16)","outcome_safety_issue":null},{"outcome_description":"Serial blood samples were collected at indicated time points for intensive PK assessment.","outcome_measure":"Area under the concentration-time curve in one dosing interval (AUC [tau]) of BMS-955176/GSK3532795","outcome_time_frame":"Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 (evening pre-dose) and 24 hours (morning pre-dose) at Week 2 (Days 12 to 16)","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"05/12/2015 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"205891"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}